Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells
Figure 4
LBH589 reduces osteosarcoma tumour growth and drives osteoblast differentiation in vivo. (a) U2OS xenograft flank tumours treated with vehicle control or 10 mg/kg LBH589 i.p. daily for 6 days. Bar = 5 mm. (b) Tumour volume. Mean ± SEM. (c) Percentage body weight. Mean ± SEM. (d) Quantitative real-time PCR of U2OS xenograft tumours following 6 consecutive days of treatment with vehicle control for expression of osteoblast differentiation markers. *.
